Cancer Control最新文献

{"title":"Lung Adenocarcinoma With Bone Metastases: Clinicogenomic Profiling and Insights Into Prognostic Factors.","authors":"Ahmed H Al Sharie, Rami K Jadallah, Mahmoud Z Al-Bataineh, Lana E Obeidat, Hanin Lataifeh, Mahmoud I Tarad, Mustafa Q Khasawneh, Walaa Almdallal, Tamam El-Elimat, Feras Q Alali","doi":"10.1177/10732748251325587","DOIUrl":"10.1177/10732748251325587","url":null,"abstract":"<p><p>IntroductionLung adenocarcinoma is the leading cause of cancer-related mortality worldwide. Understanding the clinicopathological profiles and genomic drivers of its metastatic patterns is a crucial step for risk stratification. Herein, we investigated the clinicogenomic features of bone metastases in lung adenocarcinoma and their prognostic value.MethodsA retrospective cohort study with a total of 4064 patients with various metastatic patterns of lung adenocarcinoma were included, obtaining relevant clinical data and genomic profiles. Patients were categorized based on the presence or absence of bone metastases. A comparative analysis of both groups in terms of demographics, disease status, somatic mutations, and microsatellite instability was carried out. Significantly different variables were tested for their association with bone metastases. Cox regression analyses were utilized to identify independent survival prognostic variables in the bone metastases sub-cohort.ResultsGender, concomitant metastases (to adrenal gland, nervous system, lymph nodes, liver, lung, mediastinum, pleura, and skin), and aberrations in <i>TP53</i>, <i>EGFR</i>, <i>KEAP1</i>, and <i>MYC</i> were associated with bone metastases in lung adenocarcinoma. Survival analyses within the bone metastases sub-cohort have illustrated the following variables to possess poor prognostic signature including age > 75, female gender, White ethnicity, distant metastases (adrenal gland, central nervous system, intra-abdominal, and liver), <i>EGFR</i> (wild type), <i>KEAP1</i> (mutant), <i>MYC</i> (mutant), <i>KRAS</i> (mutant), and <i>SMARCA4</i> (mutant).ConclusionKey clinical and genomic factors associated with lung adenocarcinoma bone metastases have been highlighted, providing exploratory insights into high-risk individuals. Future studies should be directed to validate these prognostic variables in larger, more diverse cohorts to enhance generalizability.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251325587"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis Challenges in Adult Leukemia: Insights From a Single-Center Retrospective Study in Qatar (2016-2021).","authors":"Hesham A B Aboelkhir, Yousra El Alaoui, Regina Padmanabhan, Majed Hadid, Adel Elomri, Tanvir Alam, Mohamed Amine Rejeb, Halima El Omri, Ruba Y Taha, Hesham Elsabah, Abdelfatteh El Omri","doi":"10.1177/10732748241275026","DOIUrl":"10.1177/10732748241275026","url":null,"abstract":"<p><p>ObjectivesWhile delays in leukemia detection remain an ongoing challenge in hematologic cancer care, little is known about the factors associated with these delays. This article focuses on identifying the barriers hindering timely diagnosis of leukemia through a cohort analysis (2016-2021) of 220 Acute Myeloid Leukemia (AML), 161 Chronic Myeloid Leukemia (CML), 90 Acute Lymphocytic Leukemia (ALL), and 121 Chronic Lymphocytic Leukemia (CLL) patients in Qatar.MethodsOf the 592 patients used for the study, subsets were identified and analyzed for delay (423), risk stratification (437), and leukemia stage (282).ResultsThere was an increasing trend in leukemia cases, with 32% of patients being diagnosed in the high-risk category. Out of 423 (median delay = 28 days) patients, 45% reported delayed diagnosis (median delay = 44 days). Further analysis of the association of delayed leukemia diagnosis using the univariate <math><mrow><mi>χ</mi></mrow></math>2 independence test revealed significant associations to patient referral type, and the presence of certain comorbidities and symptoms.ConclusionSignificant delays in leukemia diagnosis were identified, though the exact cause remains unclear. These delays can be attributed to factors such as patient, primary care, referral, system, and physician delays. Therefore, further investigation is imperative for improving the detection, diagnosis, and referral processes in hematologic cancers.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241275026"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision-Making for Ablation of Colorectal Liver Oligometastases Patients: A 10-Year Retrospective Study of Survival Outcomes Based on Right-Versus Left-Sided Primary Tumor Location.","authors":"Xiao-Guang Qi, Jian-Ming Li, Jian-Ping Dou, Fang-Yi Liu, Zhen Wang, Zhao-He Zhang, Ping Liang, Jie Yu","doi":"10.1177/10732748251324627","DOIUrl":"10.1177/10732748251324627","url":null,"abstract":"<p><p>ObjectiveTo develop a prognostic model for optimizing management of colorectal liver oligometastases (CLOM) patients with different primary tumor locations who underwent thermal ablation (TA).Materials and MethodsThe reporting of this retrospective study conforms to STROBE guidelines. A total of 525 CLOM patients who underwent TA from 3 hospitals between 2011 and 2021 were enrolled. Firstly, intra and extrahepatic disease-free survival (DFS) and overall survival (OS) for CLOM patients with different primary tumor locations were analyzed. Then, cox regression models were used to identify independent factors predicting OS. Finally, a prognostic score was developed to identify CLOM patients benefiting from TA. All patient details were de-identified.ResultsA total of 423 eligible patients were identified, with 762 CLOM (121 male, median age 59 years) and a median follow-up of 45.8 (IQR, 7.3-114.8) months. Independent predictors of OS were identified, including multiple liver metastases (<i>P</i> = .0085), right-sided colon cancer (<i>P</i> = .0210), tumor size ≥2 cm (<i>P</i> = .0273), and lymph node metastasis of primary colorectal cancer (<i>P</i> = .0302), termed as the \"MRSL\" score. On the basis of the best separation of MRSL score, patients were divided into high-risk (cutoff value ≥8) and low-risk groups (cutoff value <8). Further stratified analysis indicated that right-sided CLOM patients had shorter OS than left-sided patients in the high-risk group (54.9 vs 92.5 months, <i>P</i> = .0156). However, no significant difference in OS was observed between right-sided and left-sided CLOM patients in the low-risk group (97.7 vs 102.2 months, <i>P</i> = .28).ConclusionThe MRSL score-based model helps in selecting potential right-sided CLOM patients who benefit from TA.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251324627"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma.","authors":"Haoru Wang, Xin Chen, Ling He, Jinhua Cai","doi":"10.1177/10732748251315883","DOIUrl":"10.1177/10732748251315883","url":null,"abstract":"<p><strong>Background: </strong>This study compared anatomical imaging features between high-risk and non-high-risk groups in neuroblastoma with at least one image-defined risk factor (IDRF). It also assessed the diagnostic performance of these features in identifying the high-risk group.</p><p><strong>Methods: </strong>A retrospective analysis of neuroblastoma patients with at least one IDRF was conducted. Imaging features, including estimated tumor volume and IDRFs, were compared between the two groups. The diagnostic performance of these features was assessed using receiver operating characteristic (ROC) curves, and the areas under the ROC curves (AUCs) along with their 95% confidence intervals (CIs) were calculated. Additionally, to internally validate their diagnostic performance, the bootstrap resampling method with 1000 bootstrap resamples was employed.</p><p><strong>Results: </strong>The study included 255 patients (185 high-risk cases, 70 non-high-risk cases). Significant differences were found in estimated tumor volume and IDRF number between the high-risk and non-high-risk groups (<i>P</i> < 0.001). The estimated tumor volume and the IDRF number-based cluster were independent risk factors, and their combination achieved an AUC of 0.801 (95% CI: 0.747-0.848) for high-risk group diagnosis, with the average AUC of the 1000 bootstrap samples of 0.800 (95% CI: 0.798-0.802). In abdominal lesions, specific IDRF categories differed between high-risk and non-high-risk groups (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Our study reveals anatomical imaging differences between high-risk and non-high-risk groups in neuroblastoma with at least one IDRF.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251315883"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Mechanisms and Therapeutic Targets of Hepatitis B Virus Pre-S Mutant-Associated Hepatocellular Carcinoma Tumorigenesis.","authors":"Long-Bin Jeng, Wen-Ling Chan, Chiao-Fang Teng","doi":"10.1177/10732748251320492","DOIUrl":"10.1177/10732748251320492","url":null,"abstract":"<p><p><b>Background:</b> Despite significant progress in diagnosis and therapeutics, hepatocellular carcinoma (HCC) is still among the most commonly occurring and life-taking human cancers globally, raising an urgent need for discovering effective therapeutic targets.<b>Purpose:</b> Chronic hepatitis B virus (HBV) infection is a major etiological factor associated with HCC development, progression, and prognosis. Pre-S mutants are naturally occurring mutated forms of HBV large surface proteins and predict a higher risk of HCC development and recurrence. Moreover, pre-S mutants function as important HBV oncoproteins which can promote HCC tumorigenesis through initiating a variety of oncogenic signaling pathways. Targeting pre-S mutant-induced oncogenic signaling pathways displays therapeutic potential in HCC.<b>Research Design:</b> This review summarizes the underlying molecular mechanisms of pre-S mutant-associated HCC tumorigenesis and highlights their potential in serving as therapeutic targets for HCC.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320492"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.","authors":"Jia-Jun Hui, Han-Lu Yan, Sheng-Jun Ding, Bao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang","doi":"10.1177/10732748251320822","DOIUrl":"10.1177/10732748251320822","url":null,"abstract":"<p><strong>Background: </strong>This cohort study aimed to evaluate the impact of tumor burden (TB) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>Data from the POPLAR and OAK trials were extracted as the training and validation cohorts, respectively. TB was defined as the sum of the longest dimensions (blSLD) of measurable target lesions as per RECIST v1.1. The Kaplan-Meier curves and multivariate Cox regression analyses were performed to assess the association between TB with blood-tested tumor mutation burden (bTMB), PD-L1 expression, and survival outcomes. Additionally, random forest algorithms analysis was performed to evaluate the accuracy of TB in predicting 12-month mortality of NSCLC patients received atezolizumab.</p><p><strong>Results: </strong>A total of 105 patients from the POPLAR trial and 322 patients from the OAK trial were recruited in the training and validation sets, respectively. Patients with TB-L have significantly better OS than those with TB-H in the training (mOS: 15.8 months vs 6.93 months) as well as the validation (mOS: 16.0 months vs 7.59 months) cohort. The multivariate Cox regression analysis indicated that TB is an independent biomarker for OS prediction, regardless of bTMB, PD-L1 expression, and number of metastasis sites. The impact of TB on 12-month mortality was expected to be stronger with the increase of TB, suggesting that patients with a high tumor burden experienced a detrimental effect on 12-month mortality.</p><p><strong>Conclusion: </strong>TB may act as a prognostic biomarker for clinical benefit in NSCLC patients treated with immunotherapy alone. This may be potentially effective for predicting the efficacy of immunotherapy-based regimens.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320822"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Pathological Features of \"Crawling-type\" Early Gastric Carcinoma: A Retrospective Series of Eight Cases.","authors":"Kehan Li, Xiaofeng Zhuang, Bingyue Yao, Li Zhang, Qinwei Xu, Tao Chen, Jia Cao","doi":"10.1177/10732748251319486","DOIUrl":"10.1177/10732748251319486","url":null,"abstract":"<p><strong>Background: </strong>\"Crawling-type\" early gastric carcinoma (EGC) is a rare subtype of gastric cancer (GC) that is challenging to diagnose at an early stage due to its low-grade nuclear heterogeneity and morphology that mimics intestinal metaplasia. This study aimed to explore the clinical characteristics and pathological features of patients with crawling-type EGC.</p><p><strong>Methods: </strong>This case series study retrospectively included patients with crawling-type EGC who underwent endoscopic submucosal dissection (ESD) or gastrectomy at the East Hospital Affiliated to Tongji University between January 2019 and March 2022.</p><p><strong>Results: </strong>8 patients (mean age 63.5 ± 7.8 years) were included: 4 underwent ESD, and 4 underwent partial gastrectomy. In 4 patients, the tumors were primarily located in the gastric cardia and the basal gland area of the upper stomach, while the other 4 patients had tumors in the antral region. Preoperative gastroscopy revealed atrophic gastritis and intestinal metaplasia in all patients. The lesions were generally flat in morphology. Submucosal infiltration was found in only one case. Signet ring cells were present in the tumors of 5 patients. The mucinous type was observed in 7 patients. Seven tumors were of the gastrointestinal mixed type. Curative resection was achieved in all patients. No recurrence events were observed in any patient at 1 year after surgery.</p><p><strong>Conclusions: </strong>The crawling-type EGC may exhibit distinct clinical characteristics and pathological features compared with classical GC. Curative resection was achieved in all patients. The short-term prognosis of surgical treatment may be favorable.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319486"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends in Colorectal Cancer Incidence and Case Numbers among Individuals Aged 45-49 in the US During 2001-2019.","authors":"Chunmei Li, Tianle Chen, Huimin Chen, Bo Zhang, Bing Sun, Pengyang Zhou, Qiken Li, Weiping Chen","doi":"10.1177/10732748251327715","DOIUrl":"10.1177/10732748251327715","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to update the temporal trends for the incidences and case numbers of colorectal cancer (CRC) among individuals aged 45-49 in the US from 2001 to 2019.<b>Methods:</b> Patients were obtained from the National Program of Cancer Registries and Surveillance, Epidemiology and End Results Program (NPCR-SEER) database. Their age-adjusted incidence rates (AAIR) were calculated using the SEER*Stat software.<b>Results:</b> As high as 48.4% (125 604 cases) of the 259 700 early-onset CRC were diagnosed in individuals aged 45-49. Of these, 54.2% were males, and 40.7% were located in the rectum. Adenocarcinoma accounted for 93.9%, 96.5%, and 84.6% of proximal, distal colon, and rectal cancers, respectively. The incidences of proximal colon adenocarcinoma showed a significant increase, with an average annual percentage change (APC) of 0.7 from 2010 to 2019, while the case numbers remained stable from 2001 to 2019. In contrast, distal colon adenocarcinoma displayed increased incidences at an APC of 1.3 and an average increase of 17 cases annually over the study period. Rectal adenocarcinoma showed more rapid increases in incidence, with an average APC of 1.6 and an average increase of 27 cases per year. These rising incidences were predominately observed in non-Hispanic whites (NHWs). Conversely, non-Hispanic black (NHB) females showed decreased incidences of proximal and distal colon adenocarcinoma. Additionally, the incidences and case numbers for carcinoids significantly increased in the rectum but not in the colon.<b>Conclusions:</b> This study reveals distinct patterns of temporal trends in CRC incidences and case numbers among individuals aged 45-49. Further research is necessary to understand the underlying causes of the differences and to develop more effective preventive strategies to reduce the incidence of early-onset CRC.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251327715"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Adherence to Multi-Target Stool DNA Testing for Colorectal Cancer Among Asian Americans.","authors":"Mallik Greene, Mark Camardo, Quang A Le, Raja Kakuturu, A Burak Ozbay, A Mark Fendrick, Michael Dore, Paul Limburg","doi":"10.1177/10732748251330695","DOIUrl":"10.1177/10732748251330695","url":null,"abstract":"<p><p><b>Introduction:</b> Asian Americans have lower colorectal cancer (CRC) screening rates compared to other racial/ethnic groups. Given the importance of early detection and subsequent treatment in improving survival, this study examines adherence to first-time multitarget stool DNA (mt-sDNA) testing among Asian American patients.<b>Methods:</b> This retrospective study linked two data sources: Komodo Research Data + MapEnhance Komodo Lab database and the Exact Sciences Laboratories database. Asian American's 45 years and older who were first-time users of mt-sDNA testing between 2017 and 2023, with continuous insurance enrollment for two years, were included. Adherence to mt-sDNA testing was analyzed using descriptive statistics and logistic regression to identify factors associated with adherence.<b>Results:</b> The final sample included 336 288 Asian American patients, primarily covered by commercial insurance (70.3%), aged 50-75 years (80.7%), female (56.5%), living in metropolitan areas (95.4%), and under the care of a primary care physician (74.9%). Overall adherence to mt-sDNA testing was 70.9%, with significant variation by payer type ranging from 60.7% for Medicaid to 72.2% for Medicare (<i>P</i> < 0.0001). Overall adherence rates were approximately 70% across all age groups, sexes, and geographic regions but were notably high among gastroenterology (GI) provider patients (81.6%) and those receiving full digital outreach (via both SMS and email) (72.8%). Logistic regression identified several significant predictors of adherence: older age, males, coverage by commercial insurance, residing outside metropolitan areas, seeing GI providers, receiving digital outreach via SMS or both SMS and email, and preferring English.<b>Conclusion:</b> This study found that Asian American patients that were first-time users of mt-sDNA testing had high adherence rates. However, significant disparities existed within this population based on payer type and sociodemographic factors. Targeted outreach strategies are essential to reduce barriers and improve CRC screening uptake, ultimately reducing the burden of CRC in the Asian American population.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330695"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: From Diagnosis to Survivorship: How the Tumor Boards Facilitation Forum (TEFF) Shapes the Breast Cancer Journey in Pakistan.","authors":"","doi":"10.1177/10732748251331409","DOIUrl":"https://doi.org/10.1177/10732748251331409","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331409"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}